JPWO2020185593A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020185593A5 JPWO2020185593A5 JP2021552999A JP2021552999A JPWO2020185593A5 JP WO2020185593 A5 JPWO2020185593 A5 JP WO2020185593A5 JP 2021552999 A JP2021552999 A JP 2021552999A JP 2021552999 A JP2021552999 A JP 2021552999A JP WO2020185593 A5 JPWO2020185593 A5 JP WO2020185593A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- alkyl
- optionally substituted
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000005843 halogen group Chemical group 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 208000010877 cognitive disease Diseases 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 206010012289 Dementia Diseases 0.000 claims 6
- 208000032382 Ischaemic stroke Diseases 0.000 claims 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000004970 halomethyl group Chemical group 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 3
- 208000027089 Parkinsonian disease Diseases 0.000 claims 3
- 206010034010 Parkinsonism Diseases 0.000 claims 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 102100030122 Protein O-GlcNAcase Human genes 0.000 claims 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 108010045982 hexosaminidase C Proteins 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000023697 ABri amyloidosis Diseases 0.000 claims 1
- 208000017227 ADan amyloidosis Diseases 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000009093 Diffuse Neurofibrillary Tangles with Calcification Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims 1
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006061 fatal familial insomnia Diseases 0.000 claims 1
- 230000007387 gliosis Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 230000006951 hyperphosphorylation Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 206010023497 kuru Diseases 0.000 claims 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 210000003523 substantia nigra Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815553P | 2019-03-08 | 2019-03-08 | |
| US62/815,553 | 2019-03-08 | ||
| PCT/US2020/021479 WO2020185593A1 (en) | 2019-03-08 | 2020-03-06 | Azetidinyl 0-glyc0pr0tein-2-acetamid0-2-deoxy-3-d-gluc0pyran0sidase inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022524077A JP2022524077A (ja) | 2022-04-27 |
| JP2022524077A5 JP2022524077A5 (https=) | 2023-03-14 |
| JPWO2020185593A5 true JPWO2020185593A5 (https=) | 2023-03-14 |
| JP7663503B2 JP7663503B2 (ja) | 2025-04-16 |
Family
ID=69960768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552999A Active JP7663503B2 (ja) | 2019-03-08 | 2020-03-06 | アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12421224B2 (https=) |
| EP (1) | EP3935055A1 (https=) |
| JP (1) | JP7663503B2 (https=) |
| MA (1) | MA55203A (https=) |
| WO (1) | WO2020185593A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121405694A (zh) * | 2024-07-26 | 2026-01-27 | 浙江同源康医药股份有限公司 | Oga抑制剂及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| NZ628762A (en) | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| SI2953941T1 (sl) | 2013-02-11 | 2017-08-31 | Constellation Pharmaceuticals, Inc. | Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh |
| RS58768B1 (sr) * | 2013-03-14 | 2019-06-28 | Merck Patent Gmbh | Inhibitori glikozidaze |
| WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| CA3045957A1 (en) | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Monocyclic oga inhibitor compounds |
| WO2018154133A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
-
2020
- 2020-03-06 JP JP2021552999A patent/JP7663503B2/ja active Active
- 2020-03-06 MA MA055203A patent/MA55203A/fr unknown
- 2020-03-06 WO PCT/US2020/021479 patent/WO2020185593A1/en not_active Ceased
- 2020-03-06 US US17/435,125 patent/US12421224B2/en active Active
- 2020-03-06 EP EP20714094.8A patent/EP3935055A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518340A5 (https=) | ||
| JP2019510006A5 (https=) | ||
| JP2019506430A5 (https=) | ||
| JP2014503527A5 (https=) | ||
| IL295371A (en) | Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders | |
| JP2020535165A5 (https=) | ||
| JPWO2021155468A5 (https=) | ||
| JP2014501740A5 (https=) | ||
| JPWO2021155470A5 (https=) | ||
| JP2021169499A5 (https=) | ||
| JP2014527060A5 (https=) | ||
| JP2014503528A5 (https=) | ||
| JP2020519606A5 (https=) | ||
| JP2016517417A5 (https=) | ||
| JP2013056919A5 (https=) | ||
| JP2020502047A5 (https=) | ||
| SI3099687T1 (en) | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors | |
| JP2017515856A5 (https=) | ||
| JP2007534695A5 (https=) | ||
| JP2013542267A5 (https=) | ||
| JP2016535042A5 (https=) | ||
| CN110366555A (zh) | 甾族类衍生物调节剂、其制备方法和应用 | |
| JP2012532125A5 (https=) | ||
| JP2016531126A5 (https=) | ||
| JP2019533642A5 (https=) |